EDIT Stock Analysis: Buy, Sell, or Hold?
EDIT - Editas Medicine, Inc. Common Stock
$3.26
-0.04 (-1.21%)
▼
5d:
-10.68%
30d:
+23.02%
90d:
+12.8%
WAIT
LOW Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 11, 2026
28d
Get Alerted When EDIT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called EDIT this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EDIT is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EDIT is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: EDIT is currently trading at $3.26, which is considered slightly high relative to its 30-day fair value range of $2.53 to $3.35.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.72, while resistance sits at $3.81.
Market Sentiment: EDIT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.78 (+77.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.72, while resistance sits at $3.81.
Market Sentiment: EDIT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.78 (+77.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.53 -
$3.35
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.9%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 77.2% below Wall St target ($5.78)
- WARNING: Recommendation downgraded due to -10.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.53 -
$3.35
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.72
Resistance Level
$3.82
Current Trend
Strong Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.48
Wall Street Target
$5.78
(+77.2%)
Revenue Growth (YoY)
-39.2%
Profit Margin
-281.6%
Share & Embed Analysis
Last updated: July 13, 2026 9:19 AM ET
Data refreshes hourly during market hours. Next update: 10:19 AM
Data refreshes hourly during market hours. Next update: 10:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDIT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Amy Parison
SELL
474 shares
2026-03-03
Gilmore Neil O'neill
SELL
5394 shares
2026-03-03
Linda Burkly
SELL
749 shares
2026-03-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 61 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 64 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 63 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 62 BUY |
